$80 billion racketeering suit another problem for Valeant

25 August 2017
medical_legal_law_big

In another blow to embattled drugmaker Valeant Pharmaceuticals International (TSX: VRX), a major mutual fund launched a legal bid Wednesday to recoup $80 billion in losses it says it incurred through misinformation provided by the Canadian drugmaker.

To make matters worse, the suit, which was filed in a federal court in New Jersey, alleges the state’s racketeer influenced and corrupt organizations (RICO) law was infringed, meaning Lord Abbett could demand a penalty thrice as large as actually sustained losses, Bloomberg has reported.

Valeant, which has its US headquarters in New Jersey, is already facing legal action over alleged drug price manipulation, and had $162 million set aside at the end of the last quarter for “probable and estimable” legal bills.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical